Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal Candidiasis
Completed
Padagis LLC
N/A
2002-12-01
The objectives of this study were to demonstrate comparable safety and efficacy of
Terconazole Vaginal Suppositories, 80 mg(Test Product) and Terconazole Vaginal Suppositories,
80 mg(Reference Product) in the treatment of subjects with vulvovaginal candidiasis in order
to establish bioequivalence.
Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal Candidiasis
Completed
Perrigo Company
N/A
2002-12-01
The objectives of this study were to demonstrate comparable safety and efficacy of
Terconazole Vaginal Suppositories, 80 mg(Test Product) and Terconazole Vaginal Suppositories,
80 mg(Reference Product) in the treatment of subjects with vulvovaginal candidiasis in order
to establish bioequivalence.
A Study to Compare Efficacy and Safety of an Ovule Containing Terconazole, Clindamycin and Fluocinolone Versus an Ovule Containing Metronidazole, Nystatin and Fluocinolone in the Treatment of Secondary Vulvar/ or Vaginal Symptoms of Infectious Vagin
Completed
Janssen-Cilag, S.A.
Phase 3
2007-12-01
The purpose of this comparative study is to evaluate the efficacy of an ovule with triple
active agents (terconazole, clindamycin and fluocinolone) versus another ovule with triple
active agents (nystatin, metronidazole and fluocinolone) in the treatment of symptoms caused
by the presence of vaginitis (inflammation of the vagina) or bacterial vaginosis
(polymicrobial, nonspecific vaginitis associated with positive cultures of Gardnerella
vaginalis and other anaerobic organisms and a decrease in lactobacilli).
Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis
Completed
Shanghai Shyndec Pharmaceutical Co., Ltd.
Phase 4
2013-08-01
The objectives of this study were to demonstrate comparable safety and efficacy of
Terconazole Vaginal Suppositories, 80 mg and fluconazole in the treatment of subjects with
severe vulvovaginal candidiasis.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
